Clinical Scorecard: Efficacy and Safety of Modified-Release Hydrocortisone (Efmody®) in Pediatric Patients with Congenital Adrenal Hyperplasia: A Retrospective Analysis from a Registry
At a Glance
Category
Detail
Condition
Congenital Adrenal Hyperplasia (CAH)
Key Mechanisms
Steroid 21-hydroxylase deficiency leading to cortisol and aldosterone deficiency.
Target Population
Children and adolescents with CAH aged ≥12 years.
Care Setting
Pediatric endocrinology department.
Key Highlights
HMRC therapy associated with deceleration of growth velocity.
Significant reduction in morning 17OHP concentrations after switching to HMRC.
No adrenal crisis observed during HMRC treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis of CAH based on clinical and biochemical criteria.
Management
Hydrocortisone replacement therapy, with consideration for fludrocortisone in salt-wasting forms.
Monitoring & Follow-up
Regular monitoring of growth, bone age, and hormone levels.
Risks
Excessive hydrocortisone dosage may negatively affect adult height.
Patient & Prescribing Data
Children and adolescents with CAH due to 21-hydroxylase deficiency.
Mean hydrocortisone dose increased by 2.4 mg/m²/day during HMRC treatment.
Clinical Best Practices
Twice-daily dosing of HMRC to mimic physiological cortisol secretion.
Avoiding early morning ACTH surge through appropriate dosing strategies.
